HilleVax (NASDAQ:HLVX) Stock Price Down 5.3%

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) shares fell 5.3% during trading on Tuesday . The stock traded as low as $13.09 and last traded at $13.17. 23,761 shares traded hands during trading, a decline of 81% from the average session volume of 122,535 shares. The stock had previously closed at $13.91.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and issued a $28.00 price target on shares of HilleVax in a report on Thursday, March 21st.

HilleVax Stock Performance

The company has a quick ratio of 10.62, a current ratio of 10.62 and a debt-to-equity ratio of 0.10. The stock's fifty day moving average is $16.20 and its 200-day moving average is $14.65. The stock has a market cap of $646.60 million, a price-to-earnings ratio of -4.28 and a beta of 0.65.

HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings data on Wednesday, March 20th. The company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.02. On average, analysts forecast that HilleVax, Inc. will post -3.22 EPS for the current year.

Insider Buying and Selling at HilleVax

In related news, major shareholder Life Sciences X. L.P. Frazier acquired 8,850 shares of the firm's stock in a transaction on Thursday, April 4th. The shares were purchased at an average cost of $14.50 per share, for a total transaction of $128,325.00. Following the completion of the acquisition, the insider now directly owns 8,544,187 shares in the company, valued at $123,890,711.50. The purchase was disclosed in a filing with the SEC, which is available at this link. In related news, Director Aditya Kohli sold 8,866 shares of the company's stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $14.93, for a total transaction of $132,369.38. Following the completion of the sale, the director now owns 812,878 shares of the company's stock, valued at $12,136,268.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Life Sciences X. L.P. Frazier acquired 8,850 shares of the business's stock in a transaction that occurred on Thursday, April 4th. The shares were purchased at an average cost of $14.50 per share, with a total value of $128,325.00. Following the transaction, the insider now directly owns 8,544,187 shares of the company's stock, valued at $123,890,711.50. The disclosure for this purchase can be found here. Insiders have sold a total of 78,039 shares of company stock worth $986,464,242 over the last ninety days. Insiders own 29.30% of the company's stock.

Institutional Trading of HilleVax

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HLVX. Russell Investments Group Ltd. bought a new position in shares of HilleVax in the 1st quarter worth $26,000. UBS Group AG increased its holdings in HilleVax by 9,300.0% in the 4th quarter. UBS Group AG now owns 1,692 shares of the company's stock worth $28,000 after acquiring an additional 1,674 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in HilleVax by 80.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,753 shares of the company's stock worth $30,000 after acquiring an additional 781 shares during the last quarter. Federated Hermes Inc. increased its holdings in HilleVax by 80.6% in the 3rd quarter. Federated Hermes Inc. now owns 2,113 shares of the company's stock worth $28,000 after acquiring an additional 943 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in HilleVax by 57.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 2,587 shares of the company's stock worth $43,000 after acquiring an additional 943 shares during the last quarter. Institutional investors and hedge funds own 86.42% of the company's stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.